Anti-drug antibody formation against CGRP monoclonal antibodies for migraine ranges from <1% to 18%, with neutralizing antibodies even rarer, and adverse events from immunogenicity are uncommon.
<1% to ~18% ADA ratesAcross four CGRP antibodies, with adverse events from immune reactions rare for all agents
What the researchers found
ADA prevalence ranged from <1% to ~18% and neutralizing ADA from 0-12% across CGRP mAbs, with adverse events related to ADA formation rare across all four approved migraine antibodies.
Why it matters
Patients and clinicians considering long-term CGRP antibody therapy need to know whether the body will mount an immune reaction that could reduce drug effectiveness or cause side effects.
The numbers in context
20 studies; 4 CGRP mAbs; ADA <1-18%; neutralizing 0-12%; adverse events rare
How the study worked
Review of immunogenicity data from 20 studies (5 per antibody) including Phase 2, Phase 3, and long-term extension studies of eptinezumab, erenumab, fremanezumab, and galcanezumab.
Who was studied
Migraine patients in clinical trials of eptinezumab, erenumab, fremanezumab, and galcanezumab
What this study cannot tell us
Direct cross-study comparison is impossible due to lack of standardized immunogenicity assays. Long-term data (beyond trial durations) is limited. Individual patient risk factors for ADA development are not well characterized.
How to read the evidence
Comprehensive review of 20 clinical studies covering all four approved CGRP antibodies. Strong evidence base for immunogenicity assessment.
When this study was published
Published in 2021, reflecting early to moderate clinical experience with CGRP antibodies.
The bigger picture
As biologic therapies become standard care for chronic conditions like migraine, understanding immunogenicity is essential for long-term treatment planning. This review provides reassurance that immune reactions to CGRP antibodies are generally manageable and don't typically compromise treatment.
Questions still open
- Do ADAs explain why some patients stop responding to CGRP antibodies over time?
- Which patient factors predict higher immunogenicity risk?
- Would standardized ADA assays change the reported prevalence rates?
Common questions
Will my body develop immunity against my CGRP migraine drug?
Should I be tested for anti-drug antibodies while on CGRP therapy?
Read the original research
Immunogenicity of biologic therapies for migraine: a review of current evidence.
The journal of headache and pain, 22(1), 3
Citation
Cohen, Joshua M; Ning, Xiaoping; Kessler, Yoel; Rasamoelisolo, Michele; Campos, Verena Ramirez; Seminerio, Michael J; Krasenbaum, Lynda J; Shen, Honglue; Stratton, Jennifer. (2021). Immunogenicity of biologic therapies for migraine: a review of current evidence.. The journal of headache and pain, 22(1), 3. https://doi.org/10.1186/s10194-020-01211-5